Drug Profile
GSK 3174998
Alternative Names: GSK-3174998Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Head and neck cancer; Multiple myeloma
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (IV, Infusion)